Results for tag: "Beleodaq"

Beleodaq (belinostat) is a histone deacetylase inhibitor (HDACi) used to treat peripheral T-cell lymphoma (PTCL). It is the first FDA-approved HDACi for this indication. Beleodaq is a small molecule drug that works by blocking the activity of certain enzymes that are involved in the growth and spread of cancer cells. It is administered intravenously and is available in both capsule and injection form. Beleodaq is part of a larger market of leukemia drugs, which includes other HDACi drugs such as vorinostat and romidepsin, as well as monoclonal antibodies, tyrosine kinase inhibitors, and other targeted therapies. These drugs are used to treat various types of leukemia, including acute myeloid leukemia (AML), chronic myeloid leukemia (CML), and acute lymphoblastic leukemia (ALL). The companies in the Beleodaq market include Spectrum Pharmaceuticals, which manufactures and markets the drug, as well as other pharmaceutical companies such as Novartis, Pfizer, and Celgene. Show Less Read more